SomaLogic, Novartis Ink Research Agreement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic said Tuesday that it has signed a multi-year research agreement with Novartis, under which the drug firm will use SomaLogics' proteomics technology to accelerate its drug discovery and development efforts.

Larry Gold, CEO of Boulder, Colo.-based SomaLogic, said in a statement that the alliance will help Novartis "define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.